key: cord-0701215-3estgi4a
authors: Moui, Antoine; Dirou, Stéphanie; Sagan, Christine; Liberge, Renan; Defrance, Claire; Arrigoni, Pierre-Paul; Morla, Olivier; Kandel-Aznar, Christine; Cellerin, Laurent; Cavailles, Arnaud; Eschapasse, Emmanuel; Morio, Florent; Gourraud, Pierre-Antoine; Goronflot, Thomas; Tissot, Adrien; Blanc, François-Xavier
title: Immune alveolitis in interstitial lung disease: an attractive cytological profile in immunocompromised patients
date: 2022-03-05
journal: BMC Pulm Med
DOI: 10.1186/s12890-022-01871-w
sha: a6d57d37ab2b525897df3aa49fddfb1ce6f4ecab
doc_id: 701215
cord_uid: 3estgi4a

BACKGROUND: Bronchoalveolar lavage (BAL) is a major diagnostic tool in interstitial lung disease (ILD). Its use remains largely quantitative, usually focused on cell differential ratio. However, cellular morphological features provide additional valuable information. The significance of the “immune alveolitis” cytological profile, characterized by lymphocytic alveolitis with activated lymphocytes and macrophages in epithelioid transformation or foamy macrophages desquamating in cohesive clusters with lymphocytes, remains unknown in ILD. Our objective was to describe patients’ characteristics and diagnoses associated with an immune alveolitis profile in undiagnosed ILD. METHODS: We performed a monocentric retrospective observational study. Eligible patients were adults undergoing diagnostic exploration for ILD and whose BAL fluid displayed an immune alveolitis profile. For each patient, we collected clinical, radiological and biological findings as well as the final etiology of ILD. RESULTS: Between January 2012 and December 2018, 249 patients were included. Mean age was 57 ± 16 years, 140 patients (56%) were men, and 65% of patients were immunocompromised. The main etiological diagnosis was Pneumocystis pneumonia (PCP) (24%), followed by drug-induced lung disease (DILD) (20%), viral pneumonia (14%) and hypersensitivity pneumonitis (HP) (10%). All PCP were diagnosed in immunocompromised patients while HP was found in only 8% of this subgroup. DILD and viral pneumonia were also commonly diagnosed in immunocompromised patients (94% and 80%, respectively). CONCLUSION: Our study highlights the additional value of BAL qualitative description in ILD. We suggest incorporating the immune alveolitis profile for the diagnosis and management of ILD, especially in immunocompromised patients, since it guides towards specific diagnoses. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-022-01871-w.

Interstitial lung diseases (ILD) have heterogeneous etiologies. Usually, they are separated between ILD of known causes and idiopathic ILD. A large epidemiological study emphasized the importance of secondary ILDs relative to idiopathic ILD that have been classified by the American Thoracic Society (ATS) and the European Respiratory Open Access *Correspondence: antoine.moui@chu-nantes.fr † Antoine Moui and Stéphanie Dirou contributed equally to this work 1 Service de Pneumologie, l'Institut du Thorax, Hôpital Guillaume et René Laënnec, Boulevard Jacques Monod, Centre Hospitalier Universitaire de Nantes, 44093 Nantes, France Full list of author information is available at the end of the article Society (ERS) [1] [2] [3] . The etiological diagnostic approach of ILD can be difficult and requires a rigorous clinical examination, serological tests and a high resolution lung CT scan with thin section (< 2 mm) [4] [5] [6] [7] [8] . A likely diagnosis can be suggested by specific CT scan patterns [9] . In addition to CT scan analysis, a bronchoalveolar lavage (BAL) may be of great help to rule out differential diagnosis, in particular infectious diseases.

According to the nature of increased BAL fluid cell type (or alveolitis), different quantitative cytological profiles have been identified: lymphocytic (> 15% lymphocytes), neutrophilic (> 3% neutrophils) and eosinophilic alveolitis (> 1% eosinophils). However, none is specific of a single type of ILD [10] . Typical BAL findings allow to obtain a formal diagnosis in some rare ILD such as pulmonary alveolar proteinosis, lipoid pneumonia and acute eosinophilic pneumonia [11] . When analyzed together with clinical, biological and radiological data, examination of BAL has an added diagnostic value and guides towards a selection of disease. For example, lymphocytic alveolitis can be found in hypersensitivity pneumonitis (HP) or sarcoidosis [12, 13] , whereas neutrophilic alveolitis rather suggests idiopathic pulmonary fibrosis or asbestosis [10] . However, apart from macrophages with smoking related inclusions or foamy macrophages, qualitative morphological analysis of BAL cells remains poorly described.

Immune alveolitis is a morphological profile of BAL fluid characterized by an abundant cellularity, with high lymphocytes rates between 30 and 80% (rather CD8+, activated lymphocytes with more abundant cytoplasm), some eosinophilic and neutrophilic polynuclear cells, particular mast cells and macrophages that can be described as 'foamy' and/or 'in epithelioid transformation' , desquamating into cohesive clusters [14] . There is minimal literature describing such profile in HP, reflecting the pulmonary immune reaction that occurs after allergen inhalation in sensitized individuals [15] [16] [17] .

We hypothesized that immune alveolitis could also be taken into account in the diagnostic approach of ILD and restrict the suspected etiologies. We conducted the present study to evaluate the etiologies' frequency of ILD in patients with such immune alveolitis profile on BAL. Our secondary objective was to assess the association of clinical, radiological and biological factors to ILD final etiological diagnosis in this population.

In this observational, descriptive, retrospective and monocentric study conducted at the University Hospital of Nantes, France, from January 2012 to December 2018, all adults who presented with ILD, detected on a chest radiograph or a CT scan, and who underwent a BAL that revealed an immune alveolitis profile were selected by automated file extraction of medical records. BAL was performed using 90 mL of saline delivered into a lung segment affected by interstitial disease as identified by CT scan. Then, fluid was retrieved using an adjusted negative suction pressure with a target of a minimal volume ≥ 30%. BAL sample was separated in at least 4 aliquots to be sent for microbiological analyzes and for cytological examination. BAL fluid was centrifuged. Differential cell counts were obtained from slide stained with May-Grünwald-Giemsa. At least 200 cells were counted in each subject. The number of ciliated or squamous epithelial cells was noted but not included in the differential count. An immune alveolitis profile on BAL was defined by the combination of lymphocytosis (greater than 10%) and the following morphological criteria: activated lymphocytes, epithelioid transformation of macrophages, desquamation of macrophages into cohesive clusters, foamy macrophages (intra-cytoplasmic vacuoles).

For this study, patients were considered as being immunocompromised if they had a solid organ or bone marrow transplantation, or received treatment for solid or hematological cancer, or were treated by corticosteroids (at a daily dose ≥ 20 mg for at least three weeks) or any other immunosuppressive drugs.

The primary endpoint was the etiologies' frequency of ILD with an immune alveolitis profile on BAL. The final etiological diagnosis was collected in the electronic medical record until July 2019. Indeed, some etiologies were established several months after initial investigations. Some of these diagnoses may have been retained after multidisciplinary discussion or after a lung biopsy. For the uncertain diagnoses, all medical records were reviewed by an adjudication committee composed of a pulmonologist and a senior pathologist. The diagnosis of viral pneumonia was retained even in the absence of microbiological documentation when the clinical context, paraclinical data and clinical evolution were consistent with this diagnosis. In patients with intermediate fungal loads, Pneumocystis pneumonia (PCP) diagnosis was retained when the serum β-D glucans were either positive or after multidisciplinary discussion when unavailable. As secondary endpoints, we analyzed clinical, radiological and biological characteristics of patients and assessed etiologies' frequency in particular subpopulations.

The study protocol was submitted and approved by the «Délégation à la recherche clinique et à l'innovation (DRCI)» of our institution and by the «Institutional Review Board of the French-speaking Respiratory Medicine Society (Société de Pneumologie de Langue Française, SPLF)».

All analyses were conducted on the R software (version 3.3.0). Continuous variables were described according to their mean and standard deviation. Categorical variables were described as number and percentage. A univariate descriptive analysis was carried out to describe the overall population and to identify variables associated with the final etiological diagnosis (after excluding uncertain or infrequent diagnoses). We performed univariate analyses for each data item with the 5 most common etiologies. "Uncertain diagnoses" were excluded to minimize bias in the search for predictive factors. "Other diagnoses" and mycobacteria were excluded because of a small number of patients. We used the Chi-square independence test to assess the significance of the association between two categorical variables when validity test conditions were met. Otherwise, Fisher exact test was used. For continuous variables, the homogeneity of the variances and the normal distribution of the variables were first tested by the Levene and Shapiro-Wilk tests, respectively. Significance of differences in means was studied using Student's t-test when two means were compared or using a one-factor ANOVA when more than two means were compared. If conditions for applying these tests were not respected (normal distribution), we respectively used the Mann-Whitney-Wilcoxon test and the nonparametric Kruskal-Wallis test. We considered the statistical significance threshold for all tests at 5%. Multiple testing issue was tackled using the Benjamini-Hochberg method by limiting false discovery rate to 5%.

During the study period, 274 patients presented with immune alveolitis, as diagnosed by the pathologist. Among them, 25 were excluded because they did not meet the study criteria: 11 without ILD and 14 who were managed in another center and were only referred for bronchoscopy. Thus, 249 patients were analyzed.

Mean age of patients was 57 ± 16 years old and 140 (56%) were men (Table 1) . Ninety-eight patients (40%) were current or former smokers. A total of 163 patients (65%) received treatment for solid or hematological cancer, had transplantation or immunosuppressive therapy and were therefore considered as being immunocompromised. Corticosteroid was the most common immunosuppressive therapy (30% of patients) with an average daily dose of 16.5 mg (prednisone equivalent). PCP prophylaxis was given in 43 patients (17% of the general population and 26% of immunocompromised patients) and cotrimoxazole was the most frequently used drug (24 patients).

The most frequent clinical signs were dyspnea (75%), cough (58%) and fever (38%). Extra-thoracic signs (skin, eye, joint, muscle) were not uncommon (15%). Radiological patterns were heterogeneous in these patients with immune alveolitis (Table 1) . Ground glass opacities were the most frequently observed (79%), preferentially bilateral (86%) and diffuse (60%). In addition, the 21 patients whose CT scan was not performed all exhibited an interstitial syndrome on chest radiography.

Blood cell counts were normal in most patients, notably with the absence of eosinophilia and with a lymphocyte rate within the lower limits of normal (Table 1) . Pneumocystis jirovecii PCR was positive in half of the tested population (n = 89 patients).

Cytological analysis of BAL fluid found a high cellularity of 245,692 ± 350,317 cells/mL. Quantitative analysis of BAL cell populations revealed a lymphocytosis (51 ± 18%), a rate of macrophages reduced to 43 ± 17% and a rate of neutrophils and eosinophils slightly higher than normal (5 ± 8% and 1 ± 4%, respectively). Morphological analysis almost always showed activated lymphocytes (96%), desquamative macrophages into cohesive clusters (99%) and macrophages in epithelioid transformation (97%) (Fig. 1) . Presence of foamy or micro-vacuolated macrophages was frequent (75%). Quantitative and qualitative BAL analyses were not different according to smoking status (Additional file 1).

Etiological diagnoses of ILD associated with an immune alveolitis profile are shown in Fig. 2 and Table 2 . The most common diagnosis was Pneumocystis pneumonia in 59 patients (24%), followed by drug-induced lung disease (DILD) in 49 patients (20%), everolimus being the most frequently involved drug (n = 11 patients), followed by nivolumab (n = 5) and methotrexate (n = 5). Amiodarone was associated with DILD in only 3 patients (6%). Thirtyfour patients (14% of the global population) had viral pneumonia with viral identification in half of cases, respiratory syncitial virus, coronavirus and rhinovirus being the most frequently identified viruses (Additional file 2).

Ten percent of patients were diagnosed with HP (n = 25), granulomatosis (n = 25), or had uncertain diagnosis despite assessment by the adjudication committee (n = 26) ( Table 2) . 

Among the 163 immunocompromised patients, the main diagnosis was Pneumocystis pneumonia (n = 59 patients, 36%). All patients with a final diagnosis of PCP were immunocompromised compared to 8% of patients with HP. Twenty-six percent of the immunocompromised patients received PCP prophylaxis and 13 patients were diagnosed with PCP despite such prophylaxis. Four of them were taking cotrimoxazole with uncertain compliance while the 9 others received nebulized pentamidine or atovaquone. In immunocompromised patients, the second most common diagnosis was DILD (46 patients, 28%). Viral pneumonia was diagnosed in 27 patients (16%). The distribution of diagnoses was similar for patients receiving corticosteroids (75 patients, 30% of the global population). Among them, 31% had a daily dose > 15 mg equivalent prednisone and 26 patients received PCP prophylaxis (35%). No patient taking corticosteroids was diagnosed with HP.

Clinical, radiological and biological factors associated with the final etiological diagnosis are shown in Table 3 , Additional file 3 and Additional file 4. In univariate analysis, age, solid cancer, hematological cancer, solid organ or bone marrow transplantation, corticosteroid therapy, chemotherapy, or immunotherapy, immunosuppression, PCP prophylaxis, the presence of fever, dyspnea or extra-thoracic signs were all associated with immune alveolitis (Table 3) . Radiological factors associated with the etiological diagnosis were the presence of ground glass opacities, micronodules, condensations or a mosaic attenuation (Additional file 3). Finally, biological factors associated with this profile were white and red blood cells Other diagnoses 17 (7) Connective tissue disease 5 (2) 

In this retrospective analysis of 249 patients with an immune alveolitis profile on BAL, the main five ILD's etiologies were Pneumocystis pneumonia (24%), followed by DILD (20%), viral pneumonia (14%), HP (10%) and granulomatosis (10%). Immunocompromised patients represented 65% of the overall population. In this subgroup, the most frequent diagnosis was by far PCP and HP diagnosis was retained in only two cases.

To the best of our knowledge, the diagnostic contribution of the immune alveolitis morphological profile has not been previously described in patients with PCP.

However, lymphocytic alveolitis is commonly reported in PCP and prognosis relating to BAL cellular analysis has been evaluated [18] . Lymphocytosis was found with an average rate of 31% in 166 non-HIV infected patients with PCP [19] , which is consistent with our results. In addition, BAL cell type profile seems to have a prognostic value. In non-HIV infected patients, Lee et al. evaluated the prognosis impact of BAL cell profile in PCP. Alveolar lymphocytes appeared to be lower in patients with severe PCP compared to those with mild and moderate disease [19] . Recently, Gaborit et al. analyzed prognostic factors in immunocompromised patients with Pneumocystis pneumonia [20] . The presence of an immune alveolitis profile on BAL was an independent protective factor for mortality at 90 days. Based on these observations, additional investigations to evaluate the prognostic contribution of this profile in other ILDs are warranted. Immune alveolitis profile on BAL has been yet poorly explored. It is usually considered as an immuno-allergic profile, which refers to the pathophysiology that was mainly described in HP during the 90's [15] [16] [17] . Recent ATS/ERS guidelines focus on lymphocyte counts and recommend to obtain BAL fluid in cases with suggestive diagnosis of HP [21] . Even though a 40% lymphocyte threshold has been identified as an important item for the diagnosis of HP [22] , ATS/ERS guidelines do not set a lymphocyte threshold. Furthermore, immune alveolitis profile has not been detailed but could provide an additional value in distinguishing HP from others ILD related entities.

Many heterogeneous BAL cytological features can be associated with pulmonary drug toxicity and hamper BAL contribution in the diagnostic approach of DILD [23] , Morphological description of BAL cells had focused on intra alveolar foamy macrophages in amiodarone pneumonitis [24] . Apart from amiodarone (implicated in only 6% of DILD in our series), drugs that were the most frequently involved in our study were everolimus, followed by nivolumab and methotrexate.

The cytological profile of BAL has been well described in sarcoidosis and is characterized by a rather moderate lymphocytic alveolitis (about 30%) that may reach higher levels (50%) when the disease is active [25] . The significant proportion of granulomatosis associated with an immune alveolitis profile, and especially sarcoidosis, is an unexpected result of our study. In some patients with a past history of sarcoidosis, immune alveolitis was found in a context of disease recurrence, leading to a resumption of immunosuppressive therapies. In view of these findings, immune alveolitis would be more likely present in the early and active phases of the disease.

Ten percent of the population did not have a definite etiological diagnosis at the end of data collection, which highlights the difficulty associated to the ILD diagnostic work-up. BAL is a recognized diagnostic tool to investigate ILD [10] . When BAL is interpreted in combination with clinical data and HRCT findings, it holds a great potential in establishing ILD's etiology. Validation of a new BAL morphological pattern will hopefully aim to reduce ILD differential diagnoses and limit the need for surgical lung biopsy. Indeed, the 5 most common diagnoses accounted for nearly 80% of the final etiologies in our study. In addition, when the immunocompromised status was considered, the main final etiologies were reduced to three: PCP, DILD and viral pneumonia.

Results from univariate analysis highlight clinical, radiological or biological factors that can help in the diagnostic process and consequently that need to be sought. For example, fever or the absence of extra thoracic signs seem indicative factors to reduce ILD etiologies, while corticosteroids use appears to be negatively associated with HP.

Our study had some limitations. Its retrospective design led to missing data, especially regarding the search for different antibodies (e.g., anti-nuclear, or serum precipitins). Another study limitation was a potential selection bias related to its monocentricity. Indeed, our tertiary hospital is a reference center for kidney, heart, lung and bone marrow transplants. As a consequence, 65% of our population was immunocompromised. This parameter had obviously an impact on the frequency of final etiologies, especially for PCP.

In summary, this study highlights the additional value of BAL qualitative description in ILD with a detailed characterization of immune alveolitis, a poorly studied BAL profile. We suggest incorporating this profile for the diagnosis and management of ILD, especially in immunocompromised patients. Indeed, the presence of an immune alveolitis profile reduces the etiological possibilities and should systematically lead to exclude the diagnosis of PCP. The diagnostic contribution of immune alveolitis is inseparable of clinical, radiological and biological data that must be taken into account in a multidisciplinary diagnostic process.

Ascertainment of collagen vascular disease in patients presenting with interstitial lung disease

The utility of comprehensive autoantibody testing to differentiate connective tissue disease associated and idiopathic interstitial lung disease subgroup cases

Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society white paper

Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline

CT signs and patterns of lung disease

An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease

The clinical utility of bronchoalveolar lavage in diffuse parenchymal lung disease

Bird fancier's lung: a series of 86 patients

Pulmonary sarcoidosis

Cas pratiques: du lavage broncho-alvéolaire à la biopsie pulmonaire

Bronchoalveolar lavage in occupational lung diseases. Semin Respir Crit Care Med

The alveolitis of hypersensitivity pneumonitis

Effect of smoking on the lipid composition of lung lining fluid and relationship between immunostimulatory lipids, inflammatory cells and foamy macrophages in extrinsic allergic alveolitis

Prognostic value of bronchoalveolar lavage in patients with non-HIV pneumocystis pneumonia

Clinical usefulness of bronchoalveolar lavage cellular analysis and lymphocyte subsets in diffuse interstitial lung diseases

Outcome and prognostic factors of Pneumocystis jirovecii pneumonia in immunocompromised adults: a prospective observational study

Diagnosis of hypersensitivity pneumonitis in adults. An official ATS/JRS/ALAT clinical practice guideline

Identification of diagnostic criteria for chronic hypersensitivity pneumonitis. An international modified Delphi survey

Bronchoalveolar lavage in drug-induced lung disease

Lymphoid hyperplasia and eosinophilic pneumonia as histologic manifestations of amiodaroneinduced lung toxicity

Bronchoalveolar lavage in sarcoidosis. Semin Respir Crit Care Med

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris

and by The ERS Executive Committee

statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias

Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review

Not applicable

The online version contains supplementary material available at https:// doi. org/ 10. 1186/ s12890-022-01871-w. Additional file 3. Radiological characteristics of patients according to etiology and univariate analysis. Data are presented as mean ± SD or N (%). *Multiple testing issue was tackled using Benjamini-Hochberg method by limiting False Discovery Rate to 5%. Statistical significance threshold was at 3%. DILD Drug-induced lung disease; HP Hypersensitivity pneumonitis; N number; NA not applicable; PCP Pneumocystis pneumonia.Additional file 4. Biological characteristics of patients according to etiology. Data are presented as mean ± SD or N (%). *Multiple testing issue was tackled using Benjamini-Hochberg method by limiting False Discovery Rate to 5%. Statistical significance threshold was at 3%. DILD Druginduced lung disease; HP Hypersensitivity pneumonitis; N number; NA not applicable; PCP Pneumocystis pneumonia.

AMo collected, analyzed the data and wrote the first draft version of the manuscript. SD equally contributed to the writing of the manuscript. CS and FXB designed the study and supervised the manuscript writing. TG and PAG analyzed the data. RL, CD, PPA, OM, CKA, LC, AC, FM, EE and AT edited the manuscript. All authors approved the final version of the manuscript and vouch for the accuracy of the reported data. All authors read and approved the final manuscript.

This work did not benefit from any funding.

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

We received ethics approval from the «Délégation à la recherche clinique et à l'innovation (DRCI)» of the University Hospital of Nantes, and from the «Institutional Review Board of the French-speaking Respiratory Medicine Society (Société de Pneumologie de Langue Française, SPLF)». Written informed consent was not required for this work because it consists of retrospective data. All patients received a written information letter and did not express their opposition.

Not applicable.

The authors declare that they have no competing interests.Author details 1 Service de Pneumologie, l'Institut du Thorax, Hôpital Guillaume et René Laën-